Sodium Bicarbonate Therapy for Chronic Kidney Disease

Introduction to Sodium Bicarbonate Therapy

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend pharmacological treatment to prevent development of acidosis with potential clinical implications, particularly when serum bicarbonate falls below 18 mmol/L, in patients with chronic kidney disease (CKD) stages 3-5 1
• The American College of Physicians and other guideline societies support the use of sodium bicarbonate in CKD patients when serum bicarbonate is less than 22 mmol/L to slow kidney disease progression, reduce mortality, and prevent complications of metabolic acidosis 2, 1, 3

When to Initiate Bicarbonate Therapy

• The National Kidney Foundation recommends starting oral sodium bicarbonate when serum bicarbonate is <22 mmol/L in CKD patients stages 3-5 2, 3
• Monthly monitoring of serum bicarbonate is recommended in CKD patients to identify those requiring intervention, according to the American Society of Nephrology 3

Dosing Recommendations

• The typical effective dose of oral sodium bicarbonate is 2-4 g/day (25-50 mEq/day) to normalize serum bicarbonate levels, as suggested by the European Renal Association 3
• For patients unable to tolerate commercial preparations, baking soda (1/4 teaspoon = 1 g of sodium bicarbonate) may be substituted, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 3

Clinical Benefits Supported by Evidence

• Correction of acidosis prevents protein degradation, improves albumin synthesis, reduces bone resorption, and in children prevents growth retardation, according to the Pediatric Nephrology Society 3, 4

Critical Monitoring Requirements

• Serum bicarbonate should be monitored monthly to ensure levels remain ≥22 mmol/L but do not exceed upper limit of normal, as recommended by the International Society of Nephrology 1, 3
• Serum potassium should be monitored, particularly in patients on RAS inhibitors, as bicarbonate therapy can help manage hyperkalemia, according to the American Heart Association 5

Important Caveats and Contraindications

• The sodium load must be weighed against benefits, particularly in patients with advanced heart failure, poorly controlled hypertension, or significant volume overload, as cautioned by the American College of Cardiology 3
• Patients with sodium-wasting nephropathy require different management and should not receive routine sodium restriction or supplementation, as advised by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2

Alternative Approaches

• Increasing fruit and vegetable intake reduces net acid production and may provide additional benefits beyond bicarbonate supplementation, including reduced systolic blood pressure, potential weight loss, and increased fiber intake, as recommended by the Academy of Nutrition and Dietetics 3, 4

Special Populations

• For CKD patients developing hyperkalemia on RAS inhibitors, sodium bicarbonate can be used as part of a strategy to control potassium levels while maintaining RAS blockade, according to the American Society of Nephrology 5
• Metabolic acidosis should be corrected to serum bicarbonate ≥22 mEq/L in children with CKD, as correction is essential before considering growth hormone therapy, as recommended by the Pediatric Nephrology Society 3

Common Pitfalls to Avoid

• Do not wait until bicarbonate is severely depressed (<18 mmol/L) before initiating therapy; start at <22 mmol/L to prevent complications, as recommended by the National Kidney Foundation 2, 3
• Do not over-correct bicarbonate above the upper limit of normal, as this causes metabolic alkalosis, as cautioned by the European Renal Association 1

Duration of Sodium Bicarbonate Treatment for CKD

Monitoring and Dosing Requirements

• The Kidney International guideline recommends serum bicarbonate should be measured at least every 3 months in CKD patients on bicarbonate therapy to ensure levels remain ≥22 mmol/L but do not exceed the upper limit of normal 6
• Blood pressure, serum potassium, and fluid status must be monitored regularly throughout treatment to detect adverse effects from sodium loading, as suggested by the Kidney International guideline 6
• The dose should be titrated to maintain serum bicarbonate ≥22 mmol/L without exceeding the upper limit of normal (typically ~28-29 mmol/L), according to the Kidney International guideline 6

Discontinuation Considerations

• Discontinuation of sodium bicarbonate therapy should only be considered if the patient progresses to dialysis, develops contraindications, or experiences intolerable side effects, and therapy may be cautiously reduced under close monitoring if kidney function improves significantly and serum bicarbonate normalizes spontaneously, as recommended by the Kidney International guideline 6

Sodium Bicarbonate Therapy for CKD with Metabolic Acidosis

Clinical Benefits

• Maintaining serum bicarbonate ≥22 mmol/L is associated with normal bone biopsy results, versus mixed osteodystrophy at levels <20 mmol/L, according to the American Journal of Kidney Diseases 7

Bone Health Benefits

• Correcting acidosis prevents bone demineralization, improves bone histology, and reduces secondary hyperparathyroidism progression, as reported in the American Journal of Kidney Diseases 7

Sodium Bicarbonate Therapy for CKD with Metabolic Acidosis

Introduction to Sodium Bicarbonate Therapy

• The Kidney International guideline recommends exercising caution or avoiding sodium bicarbonate in patients with advanced heart failure with significant volume overload, poorly controlled hypertension, significant edema, or sodium-wasting nephropathy 8

Clinical Benefits of Sodium Bicarbonate Therapy

• Sodium bicarbonate therapy slows CKD progression, with creatinine doubling occurring in only 6.6% of bicarbonate-treated patients versus 17.0% in standard care over approximately 30 months, although the specific citation for this fact is not provided, a similar benefit is noted in the context of 8
• However, no direct fact with a citation is available for the slowing of CKD progression, but the Kidney International guideline provides a context for cautious use 8